Edward H van der Horst

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Venues

Nature communications

Antibodies (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Thisted, F Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H Martin, Yoshiko Takeuchi, Kader Thiam, Robert D Schreiber, Edward H van der Horst
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nature communications 15 (1) (2024)
Thomas Thisted, F Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H Martin, Yoshiko Takeuchi, Kader Thiam, Robert D Schreiber, Edward H van der Horst
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nature communications 15 (1) (2024)
Thomas Thisted, F Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H Martin, Yoshiko Takeuchi, Kader Thiam, Robert D Schreiber, Edward H van der Horst
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nature communications 15 (1) (2024)
Thomas Thisted, F Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H Martin, Yoshiko Takeuchi, Kader Thiam, Robert D Schreiber, Edward H van der Horst
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. Nature communications 15 (1) (2024)
F Donelson Smith, Robert H Pierce, Thomas Thisted, Edward H van der Horst
Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics. Antibodies (Basel, Switzerland) 12 (3) (2023)

Edward H van der Horst.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Edward H van der Horst